Amgen IncNASDAQ:AMGN
- LAST PRICE337.3800
- TODAY'S CHANGE (%)1.4300 (0.4257%)
- Bid / Lots335.1000/ 1
- Ask / Lots337.3800/ 6
- Open / Previous Close335.1500 / 335.9500
- Day Range
- 52 Week Range
- Volume4,068,245
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
Yesterday
DJ Update: Novo's Wegovy Gets Backing of a Regulator for Heart Condition Treatment. FDA Could Be Next. -- Barrons.com, from 9:55AM ET on Friday Sep 20, 2024 by Dow Jones
9:55AM ET on Friday Sep 20, 2024 by Dow Jones
Sep 13, 2024
AMGEN TO PRESENT DATA FROM MULTIPLE EARLY-STAGE CLINICAL TRIALS AT ESMO 2024, from 9:00AM ET on Friday Sep 13, 2024 by Dow Jones
9:00AM ET on Friday Sep 13, 2024 by Dow Jones
Sep 9, 2024
AMGEN PRESENTS NEW DATA FOR FIRST-IN-CLASS IMDELLTRA(TM) (TARLATAMAB-DLLE) IN SMALL CELL LUNG CANCER AT WCLC 2024, from 9:00AM ET on Monday Sep 09, 2024 by Dow Jones
9:00AM ET on Monday Sep 09, 2024 by Dow Jones
Sep 3, 2024
DJ Novo, Amgen, Other Pharma Stocks Have Clinical Trials That Could Send Them Soaring -- Barrons.com, from 12:00AM ET on Tuesday Sep 03, 2024 by Dow Jones
12:00AM ET on Tuesday Sep 03, 2024 by Dow Jones
Aug 30, 2024
AMGEN TO PRESENT AT THE 2024 WELLS FARGO HEALTHCARE CONFERENCE, from 4:00PM ET on Friday Aug 30, 2024 by Dow Jones
4:00PM ET on Friday Aug 30, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Amgen Inc | 180.5B | 58.1x | -0.22% |
Gilead Sciences Inc | 104.5B | 102.5x | +1.53% |
AstraZeneca PLC | 245.0B | 38.0x | +17.52% |
Haleon PLC | 47.1B | 33.6x | --- |
Bristol-Myers Squibb Co | 99.4B | -15.2x | +4.90% |
Novartis AG | 254.3B | 23.7x | -5.59% |
Company Information
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and improve people's lives. It operates in human therapeutics segment. The Company’s marketed products portfolio includes Aranesp, ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine), KYPROLIS (carfilzomib), Maridebart cafraglutide, (infliximab-axxq), Evenity, LumaKras, Nplate and XGeva, others.
Contact Information
- Headquarters
- One Amgen Center DriveTHOUSAND OAKS, CA, United States 91320
- Phone
- 805-447-1000
- Fax
- 805-447-1010
Executives
- Chairman of the Board, President, Chief Executive Officer
- Robert Bradway
- Chief Financial Officer, Executive Vice President
- Peter Griffith
- Executive Vice President, Chief Technology Officer
- David Reese
- Executive Vice President, Research and Development, and Chief Scientific Officer
- James Bradner
- Executive Vice President, General Counsel, Secretary
- Jonathan Graham
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $181.3B |
|---|---|
Revenue (TTM) | $30.9B |
Shares Outstanding | 537.3M |
Dividend Yield | 2.67% |
Annual Dividend Rate | 9.0000 USD |
Ex-Dividend Date | 08-16-24 |
Pay Date | 09-06-24 |
Beta | 0.61 |
EPS | $5.81 |
Book Value | $11.64 |
P/E Ratio | 58.1x |
Price/Sales (TTM) | 5.9 |
Price/Cash Flow (TTM) | 22.1x |
Operating Margin | 20.81% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
